The Medical Advisor

This review article explores a superbly designed, highly navigable website that has continuously updated the evidence-based research on early COVID-19 treatments since June 2020. The website is so exhaustively comprehensive that it could be considered a journal in itself, produced by a team of competent, committed editors. Although this singular resource has been developed and posted anonymously, one observer commented on Reddit, “It doesn’t really matter who built it, IMO. All studies are referenced/linked.” The Website Itself: The Home Page is at c19early.com The studies for COVID’s readily-available, low-cost, and evidence-based early treatments are divided into sections: Ivermectin, Proxalutamide, Budesonide, Vitamin D, Quercetin, Hydroxychloroquine, Vitamin C, Zinc and many more. A global list of COVID-19 treatment studies and outcomes, divided into early treatment and late treatment results, and complete with links and abstracts, is available at this site. The project has kept up

Molnupiravir same as ivermectin? Merck has a new antiviral drug, molnupiravir, that was being designed to treat influenza, but now is touted as a drug for COVID-19. As the FDA considers Merck’s request to bring it to market, retired nurse lecturer John Campbell, Ph.D., makes a critical comparison of the two in a YouTube video. To be upfront, Campbell says he is pro-vaccine and pro-antiviral. Ivermectin, he says, is one of the most-studied, repurposed drugs and, it’s not only FDA-approved for humans, but it won a Nobel prize as it “revolutionized the human treatment of a parasitic disease.” It also has demonstrated “broad spectrum antiviral activity against many viruses including HIV, Zika and MERS” and it inhibits the replication of the SARS coronavirus, and in fact got rid of 99.98% of SARS-viable particles in 48 hours. Like ivermectin, molnupiravir is an oral drug, but it’s converted in the liver, and there is a safety concern th

Ivermectin for Prevention and Treatment of COVID-19 Infection  A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx Background  The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets. Most trials were registered, self-funded, and undertaken by clinicians. Areas of uncertainty: We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two

The claim: Inhaling hydrogen peroxide through a nebulizer will treat COVID-19 Since the early stages of the coronavirus pandemic, vaccine skeptics have promoted a growing number of unproven at-home remedies to treat and prevent infection with the virus. Add hydrogen peroxide to that list. Some social media users claim  inhaling hydrogen peroxide  through a nebulizer, a device used to administer medicine in a mist, can prevent or cure COVID-19.  “0.5% Hydrogen Peroxide Inhalation Therapy kills viruses, bacteria, pathogens in the sinuses, throat and lungs,” reads the caption of a  Sept. 23 Facebook video , which accumulated more than 300 views within a couple of days. “Just fill the nebulizer cup with 7ml of saline solution or water and 1ml 3% hydrogen peroxide.”  The video, shared by the Facebook page Hydrogen Peroxide Nebulization, shows a toddler inhaling hydrogen peroxide. The page claimed the method is an “effective safe treatment with zero side